Yu‐Tzu Tai

25.9k citations

271 papers · 15.1k indexed · 7 hit papers · h-index 67

Hematology top 0.05%
- Multiple Myeloma Research and Treatments 184
Oncology top 0.2%
- Peptidase Inhibition and Analysis 40
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 23
Immunology top 0.5%
- Immunotherapy and Immune Responses 26
Molecular Biology top 0.5%
- Protein Degradation and Inhibitors 51
- Ubiquitin and proteasome pathways 27
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 34
Pathology and Forensic Medicine
- Cancer Mechanisms and Therapy 25

Co-authors: Kenneth C. Anderson Teru Hideshima Nikhil C. Munshi Dharminder Chauhan Paul G. Richardson Noopur Raje Klaus Podar Steven P. Treon
Cited by: Hematology Oncology Genetics
Journals: Cell (1 paper)Proceedings of the National Academy of Sciences (1 paper)Journal of Biological Chemistry (3 papers)
Partner nations: United States China Italy

In The Last Decade

Yu‐Tzu Tai

265 papers receiving 14.9k citations

Hit Papers

7 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2021 Nature Communications
2014 Blood
2010 The Journal of Immunology
2003 Blood
2001 Blood
2000 Blood
1997 Cell

Peers

Countries citing papers authored by Yu‐Tzu Tai

Since Specialization

Citations

This map shows the geographic impact of Yu‐Tzu Tai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu‐Tzu Tai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu‐Tzu Tai more than expected).

Fields of papers citing papers by Yu‐Tzu Tai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu‐Tzu Tai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu‐Tzu Tai. The network helps show where Yu‐Tzu Tai may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yu‐Tzu Tai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yu‐Tzu Tai Line = papers co-authored together Yu‐Tzu Tai links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma Blood ·Subodh Kumar,Srikanth Talluri,Jiangning Zhao,Chengcheng Liao,Lakshmi B. Potluri,Leutz Buon,Shidai Mu,Jialan Shi,Chandraditya Chakraborty,Yu‐Tzu Tai,Mehmet Samur,Nikhil C. Munshi,Masood A. Shammas	2023	3
2	BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression Clinical Cancer Research ·Lijie Xing,Su Wang,Jiye Liu,Tengteng Yu,Hailin Chen,Kenneth Wen,Yuyin Li,Liang Lin,Phillip A. Hsieh,Shih‐Feng Cho,Gang An,Lugui Qiu,Krista Kinneer,Nikhil C. Munshi,Kenneth C. Anderson,Yu‐Tzu Tai	2021	22
3	Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation Blood Cancer Discovery ·Annamaria Gullà,Eugenio Morelli,Mehmet Samur,Cirino Botta,Teru Hideshima,Giada Bianchi,Mariateresa Fulciniti,Stefano Malvestiti,Rao Prabhala,Srikanth Talluri,Kenneth Wen,Yu‐Tzu Tai,Paul G. Richardson,Dharminder Chauhan,Tomasz Sewastianik,Ruben D. Carrasco,Nikhil C. Munshi,Kenneth C. Anderson	2021	92
4	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment Blood Cancer Discovery ·Giada Bianchi,Peter G. Czarnecki,Matthew Ho,Aldo M. Roccaro,Antonio Sacco,Yawara Kawano,Annamaria Gullà,Anıl Aktaş Samur,Tianzeng Chen,Kenneth Wen,Yu‐Tzu Tai,Maria Moscvin,Xinchen Wu,Gulden Camci‐Unal,Matteo Da Vià,Niccolò Bolli,Tomasz Sewastianik,Ruben D. Carrasco,Irene M. Ghobrial,Kenneth C. Anderson	2021	12
5	Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a Molecular Cancer Research ·Tengteng Yu,Chenxing Du,Xiaoke Ma,Weiwei Sui,Zhen Yu,Lanting Liu,Lei Zhao,Zhongqing Li,Jie Xu,Xiaojing Wei,Wen Zhou,Shuhui Deng,Dehui Zou,Gang An,Yu‐Tzu Tai,Guido Tricot,Kenneth C. Anderson,Lugui Qiu,Fenghuang Zhan,Mu Hao	2020	21
6	Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma Leukemia ·Liang Lin,Shih‐Feng Cho,Lijie Xing,Kenneth Wen,Yuyin Li,Tengteng Yu,Phillip A. Hsieh,Hailin Chen,Metin Kurtoğlu,Yi Zhang,Charles A. Stewart,Nikhil C. Munshi,Kenneth C. Anderson,Yu‐Tzu Tai	2020	64
7	Progression signature underlies clonal evolution and dissemination of multiple myeloma Blood ·Yu J. Shen,Yuji Mishima,Jiantao Shi,Romanos Sklavenitis‐Pistofidis,Robert Redd,Michele Moschetta,Salomon Manier,Aldo M. Roccaro,Antonio Sacco,Yu‐Tzu Tai,François Mercier,Yawara Kawano,Nang Kham Su,Brianna Berrios,John G. Doench,David E. Root,Franziska Michor,David T. Scadden,Irene M. Ghobrial	2020	32
8	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma Blood Advances ·Andrea Schmidts,Maria Ormhøj,Bryan D. Choi,Allison Taylor,Amanda A. Bouffard,Irene Scarfò,Rebecca C. Larson,Matthew J. Frigault,Kathleen Gallagher,Ana P. Castaño,Lauren S. Riley,Maria L. Cabral,Angela C. Boroughs,Rubí M.-H. Velasco Cárdenas,Wolfgang W. Schamel,Jing Zhou,Sean Mackay,Yu‐Tzu Tai,Kenneth C. Anderson,Marcela V. Maus	2019	85
9	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab Molecular Cancer Therapeutics ·Ahmed T. Kurdi,Siobhan Glavey,Natalie Bezman,Amy Jhatakia,Jennifer L. Guerriero,Salomon Manier,Michele Moschetta,Yuji Mishima,Aldo M. Roccaro,Alexandre Detappe,Chia‐Jen Liu,Antonio Sacco,Daisy Huynh,Yu‐Tzu Tai,Michael Robbins,Jamil Azzi,Irene M. Ghobrial	2018	70
10	SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads Clinical Cancer Research ·Krista Kinneer,John Meekin,Arnaud Tiberghien,Yu‐Tzu Tai,Sandrina Phipps,Christine Mione Kiefer,Marlon C. Rebelatto,Nazzareno Dimasi,Alyssa Moriarty,Kyriakos P. Papadopoulos,Sriram Sridhar,Stephen J. Gregson,Michael J. Wick,Luke A. Masterson,Kenneth C. Anderson,Ronald Herbst,Philip W. Howard,David A. Tice	2018	58
11	Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma Clinical Cancer Research ·M. Sagawa,Hiroto Ohguchi,Takeshi Harada,Mehmet Samur,Yu‐Tzu Tai,Nikhil C. Munshi,Masahiro Kizaki,Teru Hideshima,Kenneth C. Anderson	2017	30
12	Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function Blood ·Matthew Ho,Jiye Liu,Alireza Kalbasi,Takeshi Harada,Teru Hideshima,Paul Dowling,Yu‐Tzu Tai,Li Zhang,Kenneth Wen,Ralph Mazitschek,Amanda McCann,Kenneth C. Anderson,Peter O’Gorman,Giada Bianchi	2017	2
13	Bone Marrow Microenvironment Induces Genomic Instability and Enables Clonal Evolution in Multiple Myeloma Blood ·Tommaso Perini,Raphaël Szalat,Mariateresa Fulciniti,Mehmet Samur,Michael Lopez,Puru Nanjappa,Kenneth Wen,Na Li,Yan Xu,Yu‐Tzu Tai,Masood A. Shammas,Kenneth C. Anderson,Fabio Ciceri,Nikhil Munshi	2017	1
14	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma Cancer Discovery ·Francesca Cottini,Teru Hideshima,Rikio Suzuki,Yu‐Tzu Tai,Giampaolo Bianchini,Paul G. Richardson,Kenneth C. Anderson,Giovanni Tonon	2015	87
15	Targeting the miR-221–222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma Cancer Research ·Jianjun Zhao,Zhang-Bo Chu,Yiguo Hu,Jianhong Lin,Zhongqiu Wang,Meng Jiang,Ming Chen,Xujun Wang,Yue Kang,Yangsheng Zhou,Tríona Ní Chonghaile,Melanie Johncilla,Yu‐Tzu Tai,Jin Q. Cheng,Antony Letai,Nikhil C. Munshi,Kenneth C. Anderson,Ruben D. Carrasco	2015	72
16	miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway Cancer Research ·Jianjun Zhao,Jianhong Lin,Di Zhu,Xujun Wang,Daniel J. Brooks,Ming Chen,Zhang-Bo Chu,Kohichi Takada,Bryan Ciccarelli,Samir Admin,Jianguo Tao,Yu‐Tzu Tai,Steven P. Treon,Geraldine Pinkus,Winston Patrick Kuo,Teru Hideshima,Mary Bouxsein,Nikhil C. Munshi,Kenneth C. Anderson,Ruben D. Carrasco	2014	159
17	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition Cancer Research ·Naoya Mimura,Teru Hideshima,Toshiyasu Shimomura,Rikio Suzuki,Hiroto Ohguchi,Ola Rizq,Shohei Kikuchi,Yasuhiro Yoshida,Francesca Cottini,Jana Jakubı́ková,Diana Cirstea,Güllü Görgün,Jiro Minami,Yu‐Tzu Tai,Paul G. Richardson,Teruhiro Utsugi,Atsushi Iwama,Kenneth C. Anderson	2014	66
18	Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma Clinical Cancer Research ·Claire Fabre,Naoya Mimura,Kathryn Bobb,Sun‐Young Kong,Güllü Görgün,Diana Cirstea,Yiguo Hu,Jiro Minami,Hiroto Ohguchi,Jie Zhang,Jeffrey Meshulam,Ruben D. Carrasco,Yu‐Tzu Tai,Paul G. Richardson,Teru Hideshima,Kenneth C. Anderson	2012	66
19	Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α–Dependent Pathway in Multiple Myeloma Cancer Research ·Jing Zhang,Martin Sattler,Giovanni Tonon,Clemens Grabher,Samir Lababidi,Alexander Zimmerhackl,Marc S. Raab,Sonia Vallet,Yiming Zhou,Marie‐Astrid Cartron,Teru Hideshima,Yu‐Tzu Tai,Dharminder Chauhan,Kenneth C. Anderson,Klaus Podar	2009	76
20	Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma Cancer Research ·Klaus Podar,Marc S. Raab,Giovanni Tonon,Martin Sattler,Daniela Barilá,Jing Zhang,Yu‐Tzu Tai,Hiroshi Yasui,Noopur Raje,Ronald A. DePinho,Teru Hideshima,Dharminder Chauhan,Kenneth C. Anderson	2007	55

About Yu‐Tzu Tai

Yu‐Tzu Tai is a scholar working on Hematology, Oncology and Immunology, having authored 271 papers that have together received 15.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (184 papers), Protein Degradation and Inhibitors (51 papers), Peptidase Inhibition and Analysis (40 papers), Monoclonal and Polyclonal Antibodies Research (34 papers), Ubiquitin and proteasome pathways (27 papers), Immunotherapy and Immune Responses (26 papers), Cancer Mechanisms and Therapy (25 papers) and Chronic Lymphocytic Leukemia Research (23 papers). The work is most often cited by research in Hematology (7.1k citations), Oncology (6.6k citations) and Genetics (1.6k citations). Yu‐Tzu Tai has collaborated with scholars based in United States, China and Italy. Frequent co-authors include Kenneth C. Anderson, Teru Hideshima, Nikhil C. Munshi, Dharminder Chauhan, Paul G. Richardson, Noopur Raje, Klaus Podar, Steven P. Treon, Robert Schlossman and Boris K. Lin. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact